Skip to Main Content

Close

ASH
ASH Clinical News
ASH Image Bank Open External Link
ASH News Daily
ASH-SAP
Blood Journals
Hematology
The Hematologist
International

header search

search input Search input auto suggest

filter your search

Search

Menu

Issues
- Current issue
- All Issues
CMEOpen External Link
About

Skip Nav Destination

Issue Archive

Select Year

Issue

Volume 2025, Issue 1

December 5 2025

Hematology Cover Image for Volume 2025, Issue 1

In this Issue

Ham-Wasserman Lecture
Arterial Disease and the Hematologist
B-Cell Malignancies Common and Rare: What's New in Chronic Lymphocytic Leukemia and Rare B-Cell Disorders
Between Clots and Complications: A New Era of Anticoagulation in Cancer
Biology Based Management of Iron Toxicity and Overload in Hematology Practice
Bleeding Disorder of Unknown Cause: What Do We Know?
Challenges in Diagnosing and Managing Mucocutaneous Bleeding Disorders
Complementopathies: Modern Diagnosis and Management
Decoding the Enigma: Challenges in Classical Hematology Consultations
Down the Rabbit Hole: An Update on Histiocytic Disorders
Frontline Incorporation of Immune Targeting Agents in B-All: Triumphs and Challenges
Genomics in Pediatric Acute Leukemia Risk Stratification
Hemoglobinopathies and Increased Risk of Venous Thromboembolism
Immune Cytopenias: Addressing Challenges and Advancing Treatments
Invasion of the Immunotherapies: Where We are and Where We are Going in Leukemia, Lymphoma, and Myeloma
Molecular Diagnostics for Clinical Classical Hematologists: When to Order, What to Order, What it Means, and When to Refer to Genetics?
Monoclonal Gammopathies of Clinical Significance
Multiple Myeloma: What is the Best Induction, Consolidation, and Maintenance for Fit vs Nonfit?
Navigating Immunotherapies in Pediatric Leukemia and Lymphoma: CAR Ts, Allo-HSCT—How, When and Why?
New Age Hematopoietic Stem Cell Transplantation: Same Donors, New Prophylaxis, Novel Engineering (Adult and Pediatric Perspectives)
Now is the Time to Improve Outcomes in Diffuse Large B-Cell Lymphoma
Our Patient is Pregnant: Comanaging Obstetric Patients with Complex Hematologic Issues During their Pregnancy and Delivery
Post-SCT Maintenance Strategies in Leukemia: Who, When, and Why?
Rare Aggressive B-Cell Lymphomas: Challenge for a Pathologist, Challenge for a Clinician
Sickle Cell Therapies—The Who, What, When, and Where
Targeted Therapy for AML (Triplets and More)
The Changing Landscape of the Care of Patients with Immune-Mediated and Congenital TTP
Treatment Refinement in Multiple Myeloma
Update in Hemophilia Across the Lifespan: Novel Therapies/Gene Therapy/Issues in Older Patients
What's New and Current in the World of Bone Marrow Failure
Erratum

Table of Contents

Ham-Wasserman Lecture

Gene transfer and genome editing of T cells for cancer immunotherapy: from allogeneic HSCT to TCR gene editing

Chiara Bonini

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Arterial Disease and the Hematologist

Cryptogenic stroke: definitions and management

William J. Powers

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Managing patients with a history of arterial disease and new venous thromboembolism

Echo Deng,Freda H. Passam

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Updates in antithrombotic therapy in coronary and peripheral artery disease

Amy West Pollak

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

B-Cell Malignancies Common and Rare: What's New in Chronic Lymphocytic Leukemia and Rare B-Cell Disorders

The role of MRD monitoring and options for CLL management in relapsed/refractory disease

Brian Sworder,Tanya Siddiqi

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Updates in the management of newly diagnosed chronic lymphocytic leukemia

Kristen McClellan,Andrea Sitlinger

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

What to know about rare B-cell malignancies in 2025

Salman Fazal,Yazan Samhouri,Cyrus Khan,Haifaa Abdulhaq

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Between Clots and Complications: A New Era of Anticoagulation in Cancer

Anticoagulants in hematologic malignancies: what is the data?

Ruah Alyamany,Damon E. Houghton

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Implementation failure: thromboprophylaxis in ambulatory patients with cancer

Elena Butera,Tzu-Fei Wang,Roberto Pola,Marc Carrier

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

No shots needed: direct oral anticoagulants in cancer-associated thrombosis—10-year follow-up

Ruchi Desai,Michael Jaglal

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Biology Based Management of Iron Toxicity and Overload in Hematology Practice

Management of iron overload in adult myelodysplastic syndrome

Heather A. Leitch,Rena Buckstein

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Iron toxicity and hematopoietic cell transplantation: do we understand why iron affects transplant outcome?

Emanuele Angelucci

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

From treatment to biology and back: managing iron overload in transfused hemoglobinopathies

Thomas D. Coates

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Bleeding Disorder of Unknown Cause: What Do We Know?

Buckle up! Managing surgery in patients with bleeding disorder of unknown cause

Callie Berkowitz

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Diagnosis of bleeding disorder of unknown cause: how many tests are enough to diagnose BDUC?

Maria N. Avgeropoulos,Paula D. James

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Predictors for future bleeding in bleeding disorder of unknown cause

Tim Dreier,Dino Mehic,Cihan Ay,Johanna Gebhart,Ingrid Pabinger

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Challenges in Diagnosing and Managing Mucocutaneous Bleeding Disorders

(Un) Diagnosing von Willebrand disease

Michelle K. Brenner,Pamela A. Christopherson,Veronica H. Flood

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

What's new in hereditary hemorrhagic telangiectasia?

Raj S. Kasthuri

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

When it's not Glanzmann thrombasthenia or Bernard-Soulier syndrome: diagnosing other qualitative platelet disorders

Catherine P. M. Hayward,Subia Tasneem

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Complementopathies: Modern Diagnosis and Management

Long-term outcome and management of complement-mediated thrombotic microangiopathy/aHUS

Vahid Afshar-Kharghan

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

The varieties of therapeutic experience: navigating treatment options for patients with PNH

Marc Bienz,Christopher J. Patriquin

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Update in the diagnosis of complement-mediated thrombotic microangiopathy/atypical hemolytic uremic syndrome

Michael Arthur Cole

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Decoding the Enigma: Challenges in Classical Hematology Consultations

Anticoagulation in malignancy: the patient who bleeds and clots simultaneously

Sargam Kapoor,Andrew M. Peseski,Thomas L. Ortel

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

JAK2 wild-type erythrocytosis: concept, differential diagnosis, diagnostic steps, and treatment approaches

Natasha Szuber,Ayalew Tefferi,Naseema Gangat

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

The untransfusable patient

Kathryn E. Webert,Michelle P. Zeller

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Down the Rabbit Hole: An Update on Histiocytic Disorders

The xanthogranuloma family of histiocytic neoplasms in the molecular era: Erdheim-Chester disease and beyond

Gaurav Goyal,Ronald S. Go

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Hemophagocytic lymphohistiocytosis: do we have a solution for TMI (too much inflammation)?

Paul La Rosée,Rafal Machowicz

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Advances in the diagnosis and management of pediatric Langerhans cell histiocytosis and Rosai-Dorfman disease: therapies, biomarkers, and response assessment

Olive S. Eckstein,Nitya Gulati

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Frontline Incorporation of Immune Targeting Agents in B-All: Triumphs and Challenges

The challenge of deintensifying chemotherapy for children and adolescents with B-ALL in the immunotherapy era

Sumit Gupta,Jennifer McNeer,Maureen O'Brien,Rachel Rau,David Teachey

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Immune targeting in Ph-negative and Ph-positive B-ALL: improving outcomes and minimizing chemotherapy in adult B-ALL

Kristen M. O'Dwyer

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Sanctuary sites and extramedullary relapses in the chemo-free world: insights from immunotherapies in B-ALL

Ryan D. Cassaday

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Genomics in Pediatric Acute Leukemia Risk Stratification

Revisiting novel genomic classifiers in the era of immunotherapy for pediatric B-ALL

Ruth W. Wang'ondu,Mignon L. Loh

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Emerging genomic biomarkers in diagnosis and classification of T-cell acute lymphoblastic leukemia

Jason Xu,David T. Teachey

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Using genomics to refine pediatric AML risk stratification

Martina Pigazzi,Soheil Meshinchi,Franco Locatelli

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Hemoglobinopathies and Increased Risk of Venous Thromboembolism

Sickle cell disease: managing thromboembolism

Kavya Babu,Ted Wun

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Thalassemia and hypercoagulability

Maria Domenica Cappellini,Ali T. Taher,Irene Motta

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

When sickle cell trait is not just trait: risk of VTE

Rakhi P. Naik,Rafal Pawlinski,Nigel S. Key

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Immune Cytopenias: Addressing Challenges and Advancing Treatments

Diagnosis and management of cold agglutinin disease

Sigbjørn Berentsen

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Management of autoimmune hemolytic anemia

Wilma Barcellini,Bruno Fattizzo

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Refractory ITP: revisiting definitions, diagnostics, and management paradigms

Sandhya R. Panch,Ganesh Raman,James B. Bussel

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Invasion of the Immunotherapies: Where We are and Where We are Going in Leukemia, Lymphoma, and Myeloma

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma

Danai Dima,Rahul Banerjee,Doris K. Hansen

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight

Alexandra E. Rojek,Sonali M. Smith

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Where do immunotherapies stand in management of acute leukemia in adults?

Nicolas Boissel

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Molecular Diagnostics for Clinical Classical Hematologists: When to Order, What to Order, What it Means, and When to Refer to Genetics?

Molecular approach to cytopenia and bone marrow failure

Jayanshu Jain,Uma Borate

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Molecular diagnostics 101: how to use genetic tests in classical hematology

Andrés Caballero-Oteyza,Miranda Di Biase,Xiao P. Peng

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Molecular surprises in evaluations of red cell disorders

Yasmin Elgammal,Wenying Zhang,Theodosia A. Kalfa

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Monoclonal Gammopathies of Clinical Significance

Monoclonal gammopathy of renal significance from a hematologic perspective

Eugene Brailovski,Insara S. Jaffer,Heather J. Landau

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Monoclonal-related neuropathies: diagnosis, prognosis, and outcomes

Arnaud Jaccard,Laurent Magy,Bertrand Arnulf,Frank Bridoux,Murielle Roussel

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

POEMS syndrome: diagnosis, treatments, and outcomes

Angela Dispenzieri

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Multiple Myeloma: What is the Best Induction, Consolidation, and Maintenance for Fit vs Nonfit?

Transplant in myeloma: what is its role?

Cesar Rodriguez

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

What is the best induction for myeloma for the fit patient?

Nishi Nilesh Shah,Jonathan L. Kaufman

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Choosing the optimal maintenance strategy in multiple myeloma

Benjamin Puliafito,Diana Cirstea,Noopur Raje

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Navigating Immunotherapies in Pediatric Leukemia and Lymphoma: CAR Ts, Allo-HSCT—How, When and Why?

Have CARs stalled for non–B-cell malignancies? Where are we, and where are we going?

Sara Sillbert,Adam Lamble

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Maintenance after CAR T? Are we there yet? Reducing the risk of relapse after loss of anti-CD19 CAR T-cell persistence in ALL

Maria Gabelli,Sara Ghorashian

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

With BiTEs at the kiddie table, where do CARs come in for pediatric B-ALL?

Amanda M. Li,Shannon L. Maude

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

New Age Hematopoietic Stem Cell Transplantation: Same Donors, New Prophylaxis, Novel Engineering (Adult and Pediatric Perspectives)

Donor selection, graft engineering, and dosing oh my!

Amy Moskop,Julie-An Talano

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

New age GVHD prophylaxis regimens: what works for what donor and why

Mahasweta Gooptu,John Koreth

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

New age HCT conditioning regimens: what works and why?

Naveed Ali,Brenda M. Sandmaier

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Now is the Time to Improve Outcomes in Diffuse Large B-Cell Lymphoma

Could treatment modification based on early response assessment improve results in DLBCL?

Hari S. Raman,Jennifer L. Crombie

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Selecting the best treatment approach and optimizing sequencing strategies in large B-cell lymphoma

Gloria Iacoboni,Franck Morschhauser

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Molecular subtypes of DLBCL: are we ready to translate our knowledge into the change of treatment paradigms?

Sarah C. Rutherford

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Our Patient is Pregnant: Comanaging Obstetric Patients with Complex Hematologic Issues During their Pregnancy and Delivery

Pregnancy management for patients with bleeding disorders

Nidhi Patel,Bethany Samuelson Bannow

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

A practical approach to immune thrombocytopenia in pregnancy

Kristine Matusiak,A. Kinga Malinowski,Donald M. Arnold

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Proactive management to improve outcomes of high-risk pregnancy in people with sickle cell disease

Mofiyin A. Obadina,Lydia H. Pecker

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Post-SCT Maintenance Strategies in Leukemia: Who, When, and Why?

Peri-transplant conundrums: optimizing maintenance therapy using MRD-directed approaches

Suravi Raychaudhuri,Ryan D. Cassaday,Mary-Elizabeth M. Percival

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Post-HCT maintenance therapy for AML: who, when, why, how long?

Mark Levis

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Posttransplant cells for the win? DLI and adoptive cell therapy to eradicate MRD

Pleun Schonewille,Anna van Rhenen,Renske MT ten Ham,Moniek de Witte,Jürgen Kuball

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Rare Aggressive B-Cell Lymphomas: Challenge for a Pathologist, Challenge for a Clinician

All shades of gray in the mediastinum: do we have bright ideas about how to diagnose and treat mediastinal gray zone lymphoma in the era of targeted agents?

Clémentine Sarkozy,Alexandra Traverse-Glehen

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

High-grade B-cell lymphomas: high difficulties to diagnose and treat?

Andrew J. Davies

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

When immature plasma cells form lymphoma: how to improve on diagnostics and treatment of plasmablastic lymphoma?

Jorge J. Castillo

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Sickle Cell Therapies—The Who, What, When, and Where

Optimizing the “right” patient selection for treatment for sickle cell disease

Raffaella Colombatti,Giulia Reggiani

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Optimizing the right time to start sickle cell therapies

Olufunke Y. Martin,Seethal A. Jacob

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

The right patient, the right treatment: tailoring sickle cell disease care

Sheinei Alan,Payal Desai

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Targeted Therapy for AML (Triplets and More)

Targeted triplet therapies incorporating FLT3 or IDH inhibitors: ready for prime time?

Himachandana Atluri,Yasmin Abaza,Jessica K. Altman

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

The promise of menin inhibitors: from approval to triplet regimens

Rahul K. Thakur,Eunice S. Wang

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Triplet regimens for all: genomically agnostic approaches to improve on HMA + VEN in AML?

William Nicol,Andrew H. Wei

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

The Changing Landscape of the Care of Patients with Immune-Mediated and Congenital TTP

Tailored treatment of acute immune-mediated thrombotic thrombocytopenic purpura

Linus Alexander Völker,Paul Thomas Brinkkötter

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Challenges and opportunities in the long-term management of immune-mediated TTP

Aaron Boothby,Mouhamed Yazan Abou-Ismail,Senthil Sukumar

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Modern management of congenital thrombotic thrombocytopenic purpura (cTTP)

Alice Taylor,Marie Scully

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Treatment Refinement in Multiple Myeloma

Endless possibilities and how to exploit them? What is the optimal treatment sequence?

Rajshekhar Chakraborty,Divaya Bhutani,Suzanne Lentzsch

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Can I stop my treatment, doctor? Is MRD-guided therapy ready for prime time?

Benjamin A. Derman

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

How to approach the high-risk myeloma from induction through relapse?

Katja C. Weisel,Christoph Schaefers,Lisa B. Leypoldt

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Update in Hemophilia Across the Lifespan: Novel Therapies/Gene Therapy/Issues in Older Patients

Deconstructing gene therapy in hemophilia for the clinician

Guy Young

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

New therapies in hemophilia: extend the half-life, mimic, or rebalance?

Mark T. Reding

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

The aging hemophilia patient

Magdalena Lewandowska,Ming Y. Lim

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

What's New and Current in the World of Bone Marrow Failure

Demystifying the diagnosis and management of ICUS, CHIP, and CCUS

Zhuoer Xie,Dae Hyun Lee,Doris K. Hansen,Sanam Loghavi

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Future directions in transplantation for aplastic anemia

Akshay Sharma

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Updates in low/intermediate-risk MDS

Hetty E. Carraway

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Erratum

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

C Nze,CR Flowers

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Cover Image

Cover Image
Front Matter
Table of Contents
Back Matter

Latest
Most Read
Most Cited

What to know about rare B-cell malignancies in 2025

Diagnosis and management of cold agglutinin disease

Anticoagulants in hematologic malignancies: what is the data?

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma

American Society of Hematology
2021 L Street NW, Suite 900
Washington, DC 20036
TEL +1 202-776-0544
FAX +1 202-776-0545

ASH Publications

Blood
Blood Advances
Blood Global Hematology
Blood Immunology & Cellular Therapy
Blood Neoplasia
Blood Red Cells & Iron
Blood Vessels, Thrombosis & Hemostasis
Hematology, ASH Education Program
ASH Clinical News
ASH-SAP
The Hematologist

American Society of Hematology

ASH Home
ASH Image Bank
ASH Store

Advocacy
Education
Meetings
Research

Copyright 2025 by American Society of Hematology

Cookie Settings
Privacy Policy
Cookie Policy
Terms of Use
Contact Us

This Feature Is Available To Subscribers Only

Sign In or Create an Account